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Introduction: Epidermal growth factor receptor (EGFR) mutation 
testing has become critical in the treatment of patients with advanced 
non–small-cell lung cancer. This study involves a large cohort and 
epidemiologically unselected series of EGFR mutation testing for 
patients with nonsquamous non–small-cell lung cancer in a North 
American population to determine sample-related factors that influ-
ence success in clinical EGFR testing.
Methods: Data from consecutive cases of Canadian province-wide 
testing at a centralized diagnostic laboratory for a 24-month period 
were reviewed. Samples were tested for exon-19 deletion and exon-
21 L858R mutations using a validated polymerase chain reaction 
method with 1% to 5% detection sensitivity.
Results: From 2651 samples submitted, 2404 samples were tested 
with 2293 samples eligible for analysis (1780 histology and 513 cytol-
ogy specimens). The overall test-failure rate was 5.4% with overall 
mutation rate of 20.6%. No significant differences in the failure rate, 
mutation rate, or mutation type were found between histology and 
cytology samples. Although tumor cellularity was significantly asso-
ciated with test-success or mutation rates in histology and cytology 
specimens, respectively, mutations could be detected in all specimen 
types. Significant rates of EGFR mutation were detected in cases 
with thyroid transcription factor (TTF)-1–negative immunohisto-
chemistry (6.7%) and mucinous component (9.0%).
Conclusions: EGFR mutation testing should be attempted in any 
specimen, whether histologic or cytologic. Samples should not be 
excluded from testing based on TTF-1 status or histologic features. 
Pathologists should report the amount of available tumor for testing. 
However, suboptimal samples with a negative EGFR mutation result 
should be considered for repeat testing with an alternate sample.
Key Words: Epidermal growth factor receptor, Lung cancer, 
Fragment analysis, Cytology, TTF-1.
(J Thorac Oncol. 2014;9: 947–956)
The discoveries of genetic aberrations including mutations involving epidermal growth factor receptor (EGFR) and 
anaplastic lymphoma kinase1,2 as drivers of tumorigenesis in 
non–small-cell lung cancer (NSCLC) has established the basis 
for personalized medicine for patients with lung cancer. The 
availability of agents for effective targeted therapies has led to 
a growing interest in the molecular classification of lung can-
cer. Specific mutations in the tyrosine kinase domain of EGFR 
(exons 18 to 21) sensitize patients to tyrosine kinase inhibi-
tors with high specificity against EGFR, such as erlotinib and 
gefitinib.3,4 Exon-19 deletions and exon-21 L858R substitu-
tion5,6 represent approximately 90% of EGFR mutations that 
are sensitive to EGFR tyrosine kinase inhibitors. Mutations 
occur most often in nonsquamous NSCLC at rates of 10% to 
50%, depending on patient characteristics, including smoking 
status, ethnicity, and tumor histology.1,7–10 Attempts to stream-
line mutation testing by clinicopathological characteristics to 
predict mutation status have not been accepted as sufficiently 
discriminating to apply at the clinical level.11–13
More than 70% of patients with lung cancer present at 
advanced stage and are unresectable.11,14 Therefore, the most 
common approach to acquire tissue to establish a diagnosis is 
histologic core-needle or cytologic fine-needle biopsy (FNB).15 
Many testing centers use polymerase chain reaction (PCR) fol-
lowed by direct nucleic acid sequence analysis (Sanger sequenc-
ing) to establish mutation status. A recognized pitfall of this 
method is the significant false-negative rate (up to 30%) due to 
the requirement for high tumor cellularity.16–18 Thus, many tech-
niques to increase sensitivity for detecting mutant sequences 
have been increasingly used in clinical settings, including allele-
specific PCR or matrix-assisted laser desorption/ionization-time 
of flight (MALDI-TOF) mass spectrometry approaches.11,17–23
Although EGFR mutation testing may be routinely 
conducted on patients seen in large academic institutions, 
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tissue material for testing is often available from nonacademic 
centers with a primary focus on establishing diagnosis. A 
centralized testing model for specimens from various institu-
tions provides a cost-effective and patient-centered approach 
to avoid a second procedure to obtain additional tissue for 
molecular tests. In addition, examining tumor samples from 
eligible patients with lung cancer in a defined geographic area 
offers an opportunity to collect large-scale North American 
population-based data on yield of testing and mutation rates 
in various sample types, currently not available in the litera-
ture. In 2010, a Pan-Canadian coordinated effort was initiated 
to make EGFR mutation testing available for patients being 
considered for first-line gefitinib treatment, separate from 
anaplastic lymphoma kinase testing. To ensure uniformity in 
testing of high case volumes, five centralized testing centers 
were chosen, including University Health Network (UHN) 
Molecular Diagnostics Laboratory for patients in Ontario.
This study examines retrospectively the sample-related 
characteristics that correlate with test success and allelic 
mutation frequency rates specifically for EGFR in an epide-
miologically unselected patient population, with the goal of 
defining parameters that may help streamline and set current 
benchmarks for EGFR mutation testing.
PATIENTS AND METHODS
Patients and Samples
The results used in this analysis are from consecutive 
EGFR mutation testing conducted at the UHN through the 
EGFR Canada program for 24 months (March 16, 2010 to 
March 14, 2012), according to data analysis protocol approved 
by the UHN Research Ethics Board (Figure 1S, Supplementary 
Digital Content 1, http://links.lww.com/JTO/A602). The testing 
program was established for all patients with locally advanced 
or metastatic nonsquamous NSCLC in the province of Ontario 
(population of approximately 13 million and approximately 
19% Asian), who may be eligible for first-line gefitinib treat-
ment in Canada (Figure 2S, Supplementary Digital Content 2, 
http://links.lww.com/JTO/A603). Data were collected from the 
UHN pathology CoPath database and correlated with patient 
characteristics from the EGFR Canada database when avail-
able (Table 1S, Supplementary Digital Content 3, http://links.
lww.com/JTO/A604).
Preanalytical Data Available
Standard protocol for EGFR mutation (Figure 1S, 
Supplementary Digital Content 1, http://links.lww.com/JTO/
A602) testing included an initial review of the hematoxylin-eosin 
(HE)–stained section, prepared at the same time as unstained 
sections for DNA isolation, from the submitted tumor block. 
The slides and reports were reviewed by a pulmonary patholo-
gist (DMH and M-ST) or cytopathologist (GdCS, SLB, and 
WRG). Sample-related parameters available in original reports 
or as assessed by pathologists were recorded (see Supplementary 
Materials, Supplementary Digital Content 3, http://links.lww.
com/JTO/A604). For histology samples, pathologists marked 
the tumor areas on the HE section to guide macrodissection 
by the molecular laboratory technologists (Fig. 1). Cases with 
inadequate remaining tumor (no tumor cells remaining on HE 
section), incorrect tumor type (e.g., squamous), or duplicate 
specimen were excluded from further testing.
EGFR Mutation Testing
Mutation testing was conducted using fragment analysis 
(exon-19 deletions) and restriction fragment length polymor-
phism (exon-21 L858R) methods (see Supplementary Materials, 
Supplementary Digital Content 3, http://links.lww.com/JTO/
A604).24,25 The detection limit has been established at 1% to 5% 
by serial dilutions of relevant cell line DNA.25 A reagent control, 
negative control, and two positive controls were included with 
each run.20,24–26 All test results were reviewed by a molecular 
geneticist (SK-R and CW). Final test results were reported as (1) 
positive for exon-19 deletion, (2) positive for exon-21 L858R 
mutation, (3) negative for exon-19 deletion or exon-21 L858R 
mutation, or (4) inconclusive. With the latter result, the originat-
ing pathologist or medical oncologist was encouraged to submit 
an alternate tumor sample for further testing.
Statistical Analysis
Variables examined for significance (see Supplementary 
Materials, Supplementary Digital Content 3, http://links.lww.
com/JTO/A604) included sex, age, Asian ethnicity, smoking 
status, clinical stage, specimen type, anatomical site, diag-
nosis, mucinous component, TTF-1 immunohistochemistry 
(IHC), tumor cellularity, and laboratory of origin. Additional 
variables were recorded for histology (histologic subtype, dif-
ferentiation, and macrodissection area) and cytology samples 
(cell content, fixative, and necrosis). Factors that predicted for 
EGFR mutation and test success were analyzed using mul-
tivariate logistic regression with a backward selection algo-
rithm, using odds ratios calculated for test success versus test 
failure or mutation positive versus wild type. A Wilcoxon 
signed rank test was used to compare tumor cellularity in 
matched samples. Optimal cutpoints for tumor cellularity and 
macrodissection area were chosen by identifying the smallest 
p value for test failure, with the condition of a minimum of 
10% of data per subgroup.
Because of the absence of complete data for every case, 
a multiple imputation procedure was used to generate values 
for missing data.27,28 A separate multivariate analysis was per-
formed on cases with complete data sets (n = 1808) for com-
parison, showing the same selection of significant variables 
for test success and EGFR mutation. Thus, the multiple impu-
tation data are presented to include the larger sample size. A 
two-sided p value of 0.05 was used to assess statistical signifi-
cance. All analyses were performed using R software.29
Excluding samples representing multiple tests on the 
same lesion due to a first failed attempt potentially adds bias 
to the test-success rate. However, with the first failed sample 
included in the test-success model, the overall conclusions 
found were identical. Thus, these samples and all other dupli-
cate samples were excluded from analysis (Fig. 2).
RESULTS
Altogether 2651 consecutive samples were submit-
ted for EGFR testing during the 24-month period (Fig. 2, and 
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Table 2S, Supplementary Digital Content 3, http://links.lww.
com/JTO/A604), as per the test request protocol (Figure 2S, 
Supplementary Digital Content 2, http://links.lww.com/JTO/
A603). Samples originated from 69 pathology laboratories, 
requested by 99 clinical oncologists, and included 2039 histol-
ogy and 612 cytology samples. Preanalytical review of repre-
sentative HE sections excluded 247 samples from testing, most 
commonly due to inadequate tumor material (no tumor cells 
on HE section) remaining in the tissue or cell block (n = 192), 
removing a slightly greater percentage of cytology (12.1%) 
compared with histology samples (8.5%). Additional filtering 
found 111 samples from 55 patients with multiple submitted 
samples (Tables 3S and 4S, Supplementary Digital Content 3, 
http://links.lww.com/JTO/A604), 26 of which had two tests per-
formed on the same lesion due to an initial failed result. In total, 
2293 unique patient samples were available, including 1780 his-
tology samples (77.6%) and 513 cytology samples (22.4%). The 
majority of these samples were acquired during the 2-year test-
ing period. Of the 2293 analyzed cases, we were able to obtain 
complete patient characteristics for analysis for 1884 patients 
(82.2%), comprised predominantly of patients with clinical 
stage III and IV disease (1843, 98.4%; Table 1S, Supplementary 
Digital Content 3, http://links.lww.com/JTO/A604).
Success Rates of EGFR Mutation Testing
Among 2293 unique cases analyzed, 124 samples 
(5.4%) yielded inconclusive results because of failed PCR 
amplification. Test-failure rates between histology (5.7%) and 
cytology samples were similar (4.5%, p = 0.29). There was no 
significant correlation between test success and the laboratory 
of origin or the time between sample-acquisition procedure 
and molecular testing.
Among histology samples, tumor cellularity was posi-
tively associated with higher test-success rate (Table 1). 
Lobectomy resections showed significantly better success rates 
compared with core-needle biopsies of primary lesions and 
core-needle or excisional biopsies of metastatic lesions (Tables 
1S and 2S, Supplementary Digital Content 3, http://links.lww.
com/JTO/A604). Core-needle biopsies of primary lesions dem-
onstrated the highest test-failure rate (10.1%), as compared 
with other small biopsy samples (3.9%–6.9%). Tumor cellular-
ity 30% or more within the macrodissection area, regardless of 
the size of the area, yielded the best success rates (95.6% versus 
88.7%; Tables 1S and 5S, Supplementary Digital Content 3, 
http://links.lww.com/JTO/A604). Samples with 2 mm2 of tumor 
or larger marked for macrodissection area showed higher test-
success rates compared with samples with 2 mm2 of tumor or 
smaller (95.5% versus 82.2%; Tables 1S and 6S, Supplementary 
Digital Content 3, http://links.lww.com/JTO/A604).
Cytology samples did not show significantly differ-
ent test-success rates according to tumor cellularity (Table 
7S, Supplementary Digital Content 3, http://links.lww.com/
JTO/A604). Only overall cell content of the cell block was 
correlated significantly with test-success rates (Table 1 and 
Fig. 1), with minimal cell-content cases reporting signifi-
cantly lower test-success rate (88.0%) than cases with small 
FIGURE 1.  Quality control assessment of histology 
and cytology samples for tumor volume. A, Core-
needle biopsy of lung with 2 mm2 of tumor marked 
for macrodissection showing (B) tumor cellularity of 
70% (percentage of nucleated tumor cells com-
pared with all nucleated cells). Cell content in cell-
block cytology samples as (C) minimal: mostly blood 
clot and rare groups of nucleated cells; (D) small 
clusters: few groups of nucleated cells with uneven 
distribution throughout the section; (E) moderate: 
numerous multiple widely dispersed groups of cells; 
(F) abundant: large groups of cells throughout.
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2651 consecutive samples
2039 histology 
612 cytology
247 samples (9.3%)
173 histology (8.5%)
74 cytology (12.1%)
111 samples (4.6%)
86 histology (4.6%)
25 cytology (4.6%)
2293 unique samples  analysed
1780 histology (77.6%)
513 cytology (22.4%)
2169 successful samples (94.6%)
1679 histology (94.3%)
490 cytology (95.5%)
124  inconclusive samples (5.4%)
101 histology (5.7%)
23 cytology (4.5%)
239 Exon 19 deletions (53.6%)
166 histology (52.2%)
73 cytology (57.0%)
1723 EGFR wild-type (79.4%)
1361 histology (81.1%)
362 cytology (73.9%)
207 Exon 21 L858R (46.4%)
152 histology (47.8%)
55 cytology (43.0%)
>1 sample
per patient
Failed quality 
control review
446 EGFR mutation (20.6%)
318 histology (18.9%)
128 cytology (26.1%)
histology cytology
Inadequate material in block 141 (81.5%) 51 (68.9%)
Better sample available 7 (4.0%) 15 (20.3%)
Tumor type not appropriate 24 (13.9%) 1 (1.4%)
Cancelled by clinician 1 (0.6%) 1 (1.4%)
Block not available 0 6 (8.1%)
patients samples
Two tests on same lesion 26 52
Two synchronous lung lesions 8 16
Metachronous lung lesions 8 17
Two metastatic lesions 3 6
Lung and metastatic lesions 10 20
2404 samples tested
1866 histology (77.6%)
538 cytology (22.4%)
A
B
Primary core needle bx
19%
Primary FN bx
10%
LN FN bx
4%
Other lesions FN bx
1%
Pleural fluid
5%
Bronchial wash/brush
2%
Other cytology
1%
Lobectomy
13%
Wedge excision
6%
Metastasis excision
18%
Metastasis core
needle bx
9%
Bronchial/transbronchial bx
12%
FIGURE 2. A, CONSORT diagram and (B) distribution of all consecutive cases received for EGFR testing. bx, biopsy; FN, fine 
needle; LN, lymph node; EGFR, epidermal growth factor receptor.
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clusters to abundant cell content (94.9%–99.2%; Table 8S, 
Supplementary Digital Content 3, http://links.lww.com/JTO/
A604). Of the 253 cases with known fixative, there was no 
significant difference in test-success rates between alcohol 
(93.9%) versus formalin fixation (98.0%, p = 0.13).
Multiple Tests of Same Lesion
For 26 patients not included for analysis, multiple tests 
were performed on the same lesion often due to an initial 
inconclusive result (n = 24, 92.3%; Table 3S, Supplementary 
Digital Content 3, http://links.lww.com/JTO/A604), with eight 
patients having repeat testing using a second tissue block from 
the same histology specimen. Of the 24 samples that failed 
initially, a successful result was obtained on the second sam-
ple for 20 patients (83.3%). On average, the tumor cellularity 
was 8.5% higher from the initial failed sample to the second 
successful sample; however, this increase was not significant 
(p = 0.26). For the second successful test, the EGFR mutation 
rate is 25.0%, similar to that detected for unique samples.
EGFR Mutation Rates
Among the 2169 successfully tested cases, 446 cases 
(20.6%) harbored exon-19 deletion (239) or exon-21 L858R 
mutation (207). Patient characteristics such as female sex, 
Asian ethnicity, and nonsmokers or light smokers were 
shown to have higher mutation rates (Table 2). For histology 
samples, TTF-1–positive IHC, nonmucinous morphology, 
and well/moderately differentiated tumors were predictive 
of EGFR mutation. Lower macrodissection area (<2 mm2) 
showed a higher mutation rate although these cases repre-
sented less than 10% of the data set due to increased test 
failure with lower tumor volume available and are thus not 
statistically significant. EGFR mutations were detected in 
histologic samples with a broad range of macrodissection 
area (0.5–520 mm2) and tumor cellularity (2.5%–95%).
For cytology samples, no sample characteristics were 
predictive of mutation status in the overall model although 
tumor cellularity of 20% or more was correlated with higher 
mutation rates. However, even at tumor cellularity of less than 
20%, the mutation rate (18.2%) is comparable with histology 
samples. EGFR mutations were detected in cytology cell-block 
samples showing a range of tumor cellularity (1.0%–98.0%).
TTF-1 Status and Mucinous Component
There were 1736 successfully tested cases with known 
TTF-1 IHC status (Table 3) based on the originating labora-
tory’s IHC stain or repeat IHC stain at UHN. EGFR mutations 
TABLE 1.  Factors Associated with EGFR Mutation Test Success, Separated by Histology and Cytology Samples, Significance in 
Multivariate Analysis by p < 0.05
Variable n (%)a Successful Test (%)b Odds Ratio 95% Confidence Interval Wald p Value
Histology samples (n = 1780)c
  Specimen type
   Lobectomy 326 (18.3) 322 (98.8) 1.000
   Wedge lung biopsy 129 (7.3) 124 (96.1) 0.299 0.079–1.138 0.0767
   Bronchial/transbronchial biopsy 262 (14.7) 246 (93.9) 0.380 0.119–1.214 0.1024
   Core lung needle biopsy 404 (22.7) 363 (89.9) 0.169 0.058–0.491 0.0011
   Excision biopsy of metastasis 443 (24.9) 423 (95.5) 0.286 0.096–0.850 0.0243
   Core biopsy of metastasis 216 (12.1) 201 (93.1) 0.208 0.102–1.069 0.0064
  Tumor cellularity
   ≥30% 1423 (80.9) 1361 (95.6) 1.000
   <30% 336 (19.1) 298 (88.7) 0.599 0.390–0.922 0.0199
   Unknown 21 20 (95.2)
  Macrodissection area
   ≥2 mm2 1571 (92.1) 1500 (95.5) 1.000
   <2 mm2 135 (7.9) 111 (82.2) 0.341 0.205–0.567 <0.0001
   Unknown 74 68 (91.9)
Cytology samples (n = 513)
  Cell-block cell content
   Abundant 143 (27.8) 140 (97.9) 1.000
   Moderate 128 (25.0) 127 (99.2) 1.824 0.215–15.469 0.580
   Small clusters 118 (23.0) 112 (94.9) 0.457 0.113–1.842 0.270
   Minimal 83 (16.2) 73 (88.0) 0.171 0.046–0.635 0.008
   Unknown 41 (8.0) 38 (92.7)
Values in bold indicate statistical significance (P < 0.05).
aProportion of cases with known result in variable category.
bTest success from same variable result.
cOdds ratios adjusted for smoking status.
EGFR, epidermal growth factor receptor.
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TABLE 2.  Factors Associated with Presence of EGFR Mutation in Successful Tests, Separated by Histology and Cytology 
Samples; Significance in Multivariate Analysis by p < 0.05
Variable n (%)a EGFR+ (%)b Odds Ratio 95% Confidence Interval Wald p Value
Histology samples (n = 1679)c
  Sex
   Male 727 (43.3) 98 (13.5) 0.570 0.424–0.767 0.0002
   Female 952 (56.7) 220 (23.1) 1.000
  Smoking status
   Never/light 584 (43.0) 175 (30.0) 2.840 2.061–3.914 <0.0001
   Current/former 775 (57.0) 82 (10.6) 1.000
   Unknown 320 61 (19.1)
  Ethnicity
   Asian 162 (11.9) 79 (48.8) 4.607 3.062–6.932 <0.0001
   Non-Asian 1197 (88.1) 178 (14.9) 1.000
   Unknown 320 61 (19.1)
  TTF-1 immunohistochemistry
   Positive/patchy 1210 (81.1) 266 (22.0) 3.808 2.165–6.698 <0.0001
   Negative 282 (19.9) 15 (5.3) 1.000
   Unknown 187 37 (19.8)
  Mucinous morphology
   Mucinous 212 (12.6) 19 (9.0) 0.310 0.180–0.534 <0.0001
   Nonmucinous 1467 (87.4) 299 (20.4) 1.000
  Differentiation
   Poor 740 (53.4) 89 (12.0) 0.446 0.319–0.625 <0.0001
   Well/moderate 645 (46.6) 153 (23.7) 1.000
   Unknown 294 76 (25.9)
Cytology samples (n = 490)
  Smoking status
   Never/light 187 (44.4) 66 (35.3) 2.344 1.417–3.880 0.001
   Current/former 234 (55.6) 41 (17.5) 1.000
   Unknown 69 21 (30.4)
  Ethnicity
   Asian 65 (15.4) 34 (52.3) 3.633 2.061–6.402 <0.0001
   Non-Asian 356 (84.6) 73 (20.5) 1.000
   Unknown 69 21 (30.4)
aProportion of cases with known result in variable category.
bEGFR mutation rate from same variable result.
cOdds ratio adjusted for specimen type.
EGFR, epidermal growth factor receptor; TTF, thyroid transcription factor.
TABLE 3. EGFR Mutation Rates in Combined Histology and Cytology Samples with Mucinous Morphology vs. TTF-1 
Immunohistochemistry Results
TTF-1 Result
Total Mucinous Component Nonmucinous
n (%)a EGFR+ (%)b n (%)a EGFR+ (%)b n (%)a EGFR+ (%)b
Positive 1408 (81.1) 327 (23.2) 121 (61.7) 17 (14.0) 1287 (83.6) 310 (24.1)
Negative 328 (18.9) 21 (6.4) 75 (38.3) 2 (2.7) 253 (16.4) 19 (7.5)
Unknown 433 98 (22.7) 27 1 (3.7) 406 97 (23.9)
Total 2169 446 (20.6) 223 20 (9.0) 1946 426 (21.9)
aProportion of samples with known TTF-1 result.
bPercentage of samples tested within categories of mucinous vs. nonmucinous morphology.
EGFR, epidermal growth factor receptor; TTF, thyroid transcription factor.
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were detected in 6.4% of TTF-1–negative cases. All TTF-1–
negative EGFR-positive cases were reviewed retrospectively 
and represented predominantly metastatic samples (5 bone, 4 
pleura, 3 mediastinal lymph node (LN), 3 distant LN, and 1 
liver) versus five primary lung lesions. The samples from met-
astatic sites used positive external tissue controls (small tissue 
microarrays or separate slide controls) but did not show a posi-
tive internal tissue control (benign thyroid or lung tissue). Of 
the primary lesions reviewed, one case did not have any benign 
lung tissue for internal control, and the remaining four lung 
samples showed positive internal controls and distinct lack of 
staining in the tumor tissue (true-negative IHC result). Eleven 
of the 21 cases showed an available positive IHC cytokeratin 
staining (CK7, CAM 5.2, or pankeratin AE1/AE3) indicating 
the presence of viable tumor tissue for IHC staining.
Tumors with a mucinous component represent a larger 
proportion of TTF-1–negative samples (22.8%) compared 
with TTF-1–positive samples (8.6%, p < 0.0001). EGFR 
mutations were detected in 9.0% of cases with a mucinous 
component.
Metastatic versus Primary Lesions
In the analysis cohort, 1384 samples were from pri-
mary lung lesions (60.4%) and the remaining 909 samples 
were from metastatic sites (39.6%). All metastatic site sam-
ples showed similar test-success rates except for bone, which 
showed greater test failure (15.2%, p < 0.0001; Table 4). 
Overall, primary and metastatic sites showed similar EGFR 
mutation rates (Table 9S, Supplementary Digital Content 3, 
http://links.lww.com/JTO/A604). However, specimens from 
different metastatic sites reported variable EGFR mutation 
rates with bone, distant LNs, and pleura showing higher rates 
and brain, liver, skin, and soft tissue showing lower rates com-
pared with primary lesions.
For pleura, mediastinal, and distant LNs, histology 
(core-needle or excisional biopsy) versus cytology samples 
(FNB or fluid) were analyzed separately. Cytology samples 
were more likely to detect EGFR mutation than histology 
samples at all three sites. Histology samples for distant LNs 
and pleural metastases showed similar mutation rates as pri-
mary lesions (20.3% and 21.2%), whereas cytology samples 
detected higher mutation rates for both (37.5% and 31.1%). In 
mediastinal LNs, cytology samples showed a mutation rate of 
34.4% compared with 13.4% in histology samples.
Multiple Tumor Sites Tested
For 29 patients not included for analysis, mul-
tiple lesions or different tumor sites were tested (Table 4S, 
Supplementary Digital Content 3, http://links.lww.com/JTO/
A604). Eight patients had synchronous lung lesions, with one 
case showing discordant results (exon-19 deletion; wild type). 
Eight patients had metachronous lung lesions, with one case 
showing discordant results (original tumor wild type; second 
tumor exon-21 L858R). Three patients had two separate meta-
static sites tested with no discordant results. The remaining 10 
patients had primary and metastatic lesions tested, with one 
discordant result (primary exon-19 deletion; metastasis wild 
type) and four inconclusive results.
DISCUSSION
The results reported here represent large-cohort 
(n = 2651) population-wide testing for EGFR mutation, 
including the largest series of mutation analysis on cytol-
ogy cell-block samples (n = 612), in which patients with 
TABLE 4. EGFR Mutation Rates in Primary Lung vs. Metastatic Lesions
Site n Successful Test (%) EGFR+ (%)a Exon-19 Deletions (%)b Exon-21 L858R (%)b
Primary lung 1384 1306 (94.4) 269 (20.6) 145 (53.9) 124 (46.1)
Adrenal 16 15 (93.8) 0 — —
Bone 79 67 (84.8) 20 (29.9) 5 (25.0) 15 (75.0)
Brain 66 64 (97.0) 10 (15.6) 6 (60.0) 4 (40.0)
Liver 60 58 (96.7) 9 (15.5) 3 (33.3) 6 (66.7)
Distant LN 106 98 (92.5) 24 (24.5) 15 (62.5) 9 (37.5)
  Histology 80 74 (92.5) 15 (20.3) 8 (53.3) 7 (46.7)
  Cytology 26 24 (92.3) 9 (37.5) 7 (77.8) 2 (22.2)
Mediastinal LN 249 243 (97.6) 46 (18.9) 26 (56.5) 20 (43.5)
  Histology 182 179 (98.4) 24 (13.4) 14 (58.3) 10 (41.7)
  Cytology 67 64 (95.5) 22 (34.4) 12 (54.5) 10 (45.5)
Pericardial/peritoneal fluid 12 12 (100.0) 2 (16.7) 2 (100.0) 0
Pleura 231 221 (95.7) 59 (26.7) 34 (57.6) 25 (42.4)
  Histology 104 99 (95.2) 21 (21.2) 13 (61.9) 8 (38.1)
  Cytology 127 122 (96.1) 38 (31.1) 21 (55.3) 17 (44.7)
Skin or soft tissue 78 73 (93.6) 6 (8.2) 3 (50.0) 3 (50.0)
Other (GI tract, spleen, thymus, tonsil, bladder) 12 12 (100.0) 1 (8.3) 0 1 (100.0)
aPercentage of EGFR-positive samples from all successful tests.
bPercentage of specific mutation vs. total mutations detected.
EGFR, epidermal growth factor receptor; LN, lymph node; GI, gastrointestinal.
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nonsquamous NSCLC were analyzed at a centralized molecu-
lar testing laboratory. The results confirm an overall mutation 
rate of 20.6%, likely representative of EGFR mutation rate 
in a North American population. Using pre-existing samples 
for mutation testing allows clinicians to proceed with tar-
geted therapy without the cost, delay, and intervention of a 
repeat tissue-acquisition procedure. In this unselected testing 
situation, the vast majority of submitted samples were found 
suitable for testing, with only 5.4% failing to provide inter-
pretable results when testing is limited to exon-19 deletions 
and exon-21 L858R mutations. The failure rate may be par-
tially attributed to cases with minimal tumor volume present 
to proceed with molecular testing (any viable nucleated tumor 
cells present on the HE section). Of note, there were numerous 
successful EGFR mutation–positive cases with similar mini-
mal tumor material present at initial quality assessment; thus, 
exclusion of these cases would have precluded these patients 
from receiving EGFR-inhibitor treatment while waiting for a 
second tissue-acquisition procedure. Given the turn-around-
time for molecular results of 5 business days from the time of 
sample receipt, a sample that shows any residual tumor cells 
on the HE section reviewed at quality assessment should be 
considered for testing, even though this may yield slightly 
higher test-failure rates.
Cytology (cell-block) samples performed equivalent to 
histology samples, consistent with results from a smaller study 
by Pang et al.30 In fact, test-failure rates for primary lesions 
appeared higher for core-needle histology than FNB cytology 
samples (Table 2S, Supplementary Digital Content 3, http://
links.lww.com/JTO/A604). No particular bias was identified 
in the cytology samples for FNB of lung with respect to origi-
nating laboratory. However, one might speculate that the small 
amount of total nucleated tissue present in the macrodissected 
sections of a core-needle biopsy (often <1 mm in diameter) 
may not be sufficient tissue material overall for DNA ampli-
fication in the PCR step and may in fact be less tumor DNA 
material than a well-obtained FNB cell-block sample. If a lung 
lesion is amenable to sampling by FNB by an experienced 
operator together with rapid on-site evaluation (ROSE) by 
cytopathologist, these samples would be considered ideal for 
diagnosis and molecular testing. Interestingly, although test 
success is lower in bone specimens, perhaps related to pro-
cessing in decalcification solution, mutation rate was higher 
compared with the primary lesions.
Pathological review of the section is essential for the 
selection of optimal testing sample before molecular testing, 
with judicious usage of immunohistochemical stains to pre-
serve tumor tissue.11,31,32 From our analysis, histology samples 
containing 2 mm2 or larger tumor tissue and more than 30% 
tumor cellularity emerged as most optimal for achieving higher 
test-success rates using our testing platform. Optimal cytol-
ogy samples should contain at least a few scattered groups of 
nucleated cells (Fig. 1D, “small-clusters” cell content). Note 
that selection of these cutpoints was data driven and thus 
could suffer from type I error inflation and should be veri-
fied in future validation studies. However, as even suboptimal 
samples are documented to produce positive mutation results, 
all samples should be eligible for mutation testing, regardless 
of tumor amount.33,34 Therefore, it is important to use molecu-
lar testing methodology with adequate limit of detection to 
enable use of samples with low tumor volume.31 Furthermore, 
quantifying the amount of tumor seen at diagnosis may help 
facilitate selection of the best test sample or direct the need 
for a second procedure to acquire sufficient tissue. It is impor-
tant that clinicians be aware of potential false-negative results; 
thus, suboptimal samples with a negative result should be con-
sidered for repeat testing of an alternate tumor sample.
There is much discussion regarding the use of cytology 
samples for molecular testing,11,19,30,32–36 with preference often 
given to histology samples.37 This study shows cytology cell 
blocks are as good a source of tumor cells for mutation testing 
as histology samples, regardless of fixative (alcohol or for-
malin), necrosis, or specimen type. Unlike histology samples, 
tumor cellularity does not affect test success, and samples of 
lower tumor cellularity (<20%) remain adequate for detec-
tion of EGFR mutations at rates comparable with histology 
specimens. For mediastinal LNs, histology samples obtained 
by mediastinoscopy (n = 184) compared with FNB with 
endobronchial ultrasound guidance (EBUS) (n = 67) showed 
similar test-success rates but considerably lower mutation 
detection rate (13.4% versus 34.4%). One may speculate that 
histology specimens with prominent residual lymphoid tissue 
lead to overestimation of tumor cellularity and more challeng-
ing macrodissection that contributes to lower mutation rate. In 
contrast, FNB may preferentially obtain less cohesive tumor 
cells or remove PCR inhibitors in the cellular milieu. This 
rationale may explain the difference in mutation detection in 
distant LNs (21.3% versus 36.0%), but it does not explain the 
differences in pleura metastases diagnosed by thorascopic or 
core-needle biopsy versus pleural fluid (21.2% versus 31.1%). 
The longer duration of formalin fixation time and resultant 
DNA fragmentation in histology specimens may contribute 
to the lower mutation rate and raises the question of false-
negative results. It is worth noting that of the 64 successful 
cytology samples from mediastinal LNs, 46 were performed 
at UHN using EBUS with ROSE by a cytopathologist, focused 
on ensuring an adequate sample for cell-block preparation. 
Among these cases, 19 samples were positive for EGFR muta-
tion (41.3%) versus three of the 18 cases (16.7%) sampled at 
other institutions without ROSE. Furthermore, some EBUS 
procedures at UHN represent a partially selected population 
using patient characteristics (nonsmokers), possibly contribut-
ing to the higher mutation rate.
Consistent with previous reports, we found that female 
sex, nonsmoking or light-smoking status, Asian ethnicity, 
TTF-1–positive IHC, nonmucinous, and well-differentiated 
histology were associated with higher mutation rates.1,7–13 
With the growing expense of mutation testing, algorithmic 
approaches to stratifying cases according to mutation rates 
have been suggested, including negative TTF-1 IHC,12,13 
mucinous morphology, and metastatic site38–41 as surrogate 
markers of wild-type EGFR. In our study, mutation rates in 
TTF-1 negative tumors and tumors with mucinous compo-
nent are 6.7% and 9.0%, respectively. The significant muta-
tion rates suggest that these factors should not be used to 
exclude EGFR mutation testing. Note is made that the tumors 
955Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 7, July 2014 Population-Based EGFR Mutation Testing
with mucinous component represent a mixed group of pure 
invasive mucinous carcinomas and mixed tumors with some 
mucinous component; thus, the mutation-positive rate (9.0%) 
may be higher than the previously reported rate.31 However, 
as initial sampling of tumors is often through small biopsy 
samples, it is not always possible to ascertain if the tumor is 
pure mucinous or mixed. Furthermore, given that IHC stains 
were performed at varying institutes using different antibody 
clones for TTF-1 and the results are subject to false-negative 
quality errors, TTF-1–negative results should not be used as 
an exclusion criteria for mutation testing. Among the 21 TTF-
1–negative EGFR-positive cases, 17 samples did not include 
a positive internal tissue control (benign lung or thyroid tissue 
within the sample itself); thus, even in the setting of excellent 
IHC quality control, it is not always possible to verify that the 
TTF-1 antibody has worked on the sampled tissue. In particu-
lar, IHC results may not be considered reliable in the setting 
of decalcification (for bone specimens), and exclusion of a 
TTF-1–negative case may exclude a potential EGFR-positive 
lesion from further targeted therapy. This study also confirms 
the need to test multiple tumor sites in the same patient in 
cases of synchronous or metachronous lung tumors and the 
occurrence of rare cases of discordant results between pri-
mary versus metastatic lesions.42–44
Although there have been numerous reports on the 
result of EGFR mutation testing from clinical trials and 
single institutions, data related to test performance from 
population-based testing have been limited. The results as 
we report here show a viable centralized model for testing 
pre-existing tissue samples and may provide benchmarks in 
the quality evaluation of optimal clinical testing situation 
and laboratories.
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